LongGHJun 2026
Guardant Health
Guardant Health benefited from several company-specific catalysts during the quarter. These included FDA approval of an updated Guardant360 liquid-biopsy test, inclusion of…
GH
1 published idea on Guardant Health across 1 fund — 1 long and 0 short.
Each entry below comes from a hedge fund's own investor letter, not a 13F filing, so it carries the reasoning behind the position on Guardant Health: the full thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Guardant Health benefited from several company-specific catalysts during the quarter. These included FDA approval of an updated Guardant360 liquid-biopsy test, inclusion of…